A phase II trial of interleukin-2 in myelodysplastic syndromes

Sucha Nand*, Wendy Stock, Patrick Stiff, Jeffrey Sosman, Brenda Martone, Ruta Radvany

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Patients with myelodysplastic syndromes (MDS) show a decrease in the number and function of natural killer (NK) cells, including lymphokine activated killer (LAK) cell activity. Interleukin-2 (IL-2) stimulates the proliferation and activity of these lymphocytes. Anecdotal clinical experience has shown haematological and cytogenetic improvement in myelodysplasia by low-dose IL-2 treatment. A total of 10 patients with MDS were treated with 1 million units of IL-2 subcutaneously daily for 12 weeks. Even though improvement in CD16+/CD56+ cell numbers was seen in a majority of the patients, the haematological status and transfusion requirements remained unchanged. There was minimal toxicity from this therapy.

Original languageEnglish (US)
Pages (from-to)205-207
Number of pages3
JournalBritish Journal of Haematology
Issue number1
StatePublished - 1998


  • Interleukin-2
  • Myelodysplastic syndromes
  • Natural killer cells
  • Preleukaemia

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A phase II trial of interleukin-2 in myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this